Encouragingly, recent developments—such as anti-CD44 antibody-modified TAIII liposomes (CD44-LP) [56]—have markedly improved its pharmacokinetic profile, extending its half-life by 10.7–14.2-fold and achieving a tumor inhibition rate of 55.2% (7.2 times that of free TAIII), without significant systemic toxicity. The gene discussed is CD44; the disease is neoplasm.